Pepgen Inc stock is traded at $2.45, with a volume of 393,849. It is up +5.39% in the last 24 hours and up +5.84% over the past month. PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed that their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle, and the central nervous system. Its pipeline products are: PGN-EDO51, PGN-EDODM1, and others.
Previous Close:
$2.32
Open:
$2.33
24h Volume:
393,849
Relative Volume:
0.39
Market Cap:
$169.34M
Revenue:
-
Net Income/Loss:
-$77.22M
P/E Ratio:
-
EPS:
-$1.75
Net Cash Flow:
-$77.27M
1W Performance:
+3.60%
1M Performance:
+5.84%
6M Performance:
+32.52%
1Y Performance:
-41.92%
1-Day Range:
$2.33$2.52
1-Week Range:
$2.22$2.69
52-Week Range:
$1.31$7.80
Pepgen Inc Stock (PEPG) Company Profile
Name
Pepgen IncSector
HealthcareIndustry
BiotechnologyPhone
703-456-8000Address
1 MARINA PARK DRIVE, SUITE 900, BOSTON, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS